Patients with lymphoma or CLL who lacked confidence in their care or doctor were more likely to experience emotional distress and other psychosocial challenges.
Read More
A real-world study presented at ASCO 2025 found that patients with CLL/SLL experienced a higher risk of serious infections with one treatment regimen compared to another over 12 and 18 months.
Read More
The latest news from ASCO 2025 focusing on CLL including abstracts, features, and helpful conference information.
Read More
Zanubrutinib plus venetoclax showed promising efficacy and manageable safety in treatment-naïve CLL/SLL, including patients with del(17p) and TP53 mutations.
Read More
The 2025 ASCO Annual Meeting showcased new data on therapies for chronic lymphocytic leukemia, including zanubrutinib, acalabrutinib, and liso-cel.
Read More
We want to hear from you. Which session are you most looking forward to attending at ASCO?
Read More
